What are the manufacturers of ivonib/ivitinib?

Ivosidenib/Ivosidenib is a targeted drug targeting IDH1 mutations. It is mainly used to treat acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It is also suitable for some patients with cholangiocarcinoma. The development and production of this drug involves many pharmaceutical companies. The following are some major manufacturers and their related information.

Avosidenib's first development company isAgios Pharmaceuticals. The company focuses on developing innovative drugs for cancer and metabolic diseases, and ivonib is one of its important products in the field of oncology. Agios Pharmaceuticals received FDA approval for ivonib in 2017, making it the first drug approved to treat IDH1-mutated acute myeloid leukemia. Agios conducted a large number of clinical trials during the drug's development process to prove its efficacy and safety. This process allows ivonib to bring hope to many patients.

In addition toAgios Pharmaceuticals, ivonib is manufactured and sold by other pharmaceutical companies. Especially in the international market, many companies, including some large pharmaceutical companies, may reach licensing agreements with Agios for the distribution of drugs.

In addition, in Laos, there are also generic ivonib drugs on the market. Common manufacturers include Lucius Pharmaceuticals of Laos. The ingredients, efficacy, and specifications of the drugs they produce are basically the same as those of the original drugs, but there are differences in manufacturers and prices. Both the initial R&D company and subsequent pharmaceutical companies must comply with relevant regulations and standards for drug production. This includes the procurement of raw materials, monitoring of the production process, quality testing of finished products, etc. to ensure the safety and effectiveness of the final product.